SCYNEXIS, Inc.

NasdaqCM:SCYX Lagerbericht

Marktkapitalisierung: US$53.1m

SCYNEXIS Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

SCYNEXIS hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-45.4%

Rückkaufsrendite

Gesamte Aktionärsrendite-45.4%
Zukünftige Dividendenrenditen/a
Wachstum der Dividenden/a
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Ausschüttungsquoten/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Analyseartikel • Jan 23

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Sep 09

Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • May 17

Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Aug 08

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Jun 19

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

The SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price has softened a substantial 32% over the previous 30 days, handing back...
Analyseartikel • May 12

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a good week for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, because the company has just released its latest...
Analyseartikel • Apr 04

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Apr 02

Scynexis: Update Following Restructuring Of GSK Deal

Summary Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years, not accounting for pending milestones. Just the milestones from delivery of readouts to GSK and resumption and progress of MARIO trial are expected to cover all 2024 operating expenses. SCYX stock is undervalued in the short/medium term, but its long-term success is unclear considering emerging competition and pipeline limited to SCY-247. Read the full article on Seeking Alpha
Analyseartikel • Feb 01

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

With a price-to-sales (or "P/S") ratio of 0.6x SCYNEXIS, Inc. ( NASDAQ:SCYX ) may be sending very bullish signals at...
Analyseartikel • Dec 21

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Sep 26

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares have had a horrible month, losing 28% after a relatively good period beforehand...
Analyseartikel • Aug 17

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 26

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Summary SCYX has a commercial antifungal Brexafemme. However, we are neutral on its commercial potential as discussed in our previous article. No big pharma deal materialized, and the company raised USD45M through pre-funded warrant offerings. The drug's true upside is in systemic fungal infection; however, catalysts are expected in 2024-2025 at the earliest making the stock uninvestible at this time. We downgrade SCYX to a sell rating. Background As described in detail in our initiation of coverage, we have established an option size position on SCYX based on a potential big pharma M&A and undoubtedly cheap valuation (negative EV) of the company. However, with the recent messy financing deal (described in detail below) and lack of near-term clinical catalyst, we decided to sell out of the position and downgrade the stock. Our rationale is described below. Catalysts are expected in 2024-2025 the earliest The absence of short-term catalysts makes it un-investible for short-mid-term investors in our view. We think the major value driver of the stock is in the systemic infection space, where the catalysts are expected in 2024-2025 (as shown below). Of note, the company announced that the FDA has accepted SCYX's submission of a supplemental New Drug Application regarding label expansion of BREXAFEMME to include "prevention of recurrent vulvovaginal candidiasis" and the target PDUFA date is Nov 2022. We believe the label extension is fully priced in and any positive news will be a selling opportunity for this ticker. SCYX Homepage Messy pre-funded warrants make SCYX uninvestible in our view SCYNEXIS priced its earlier announced underwritten public offering of 3.33M shares of its common stock, prefunded warrants to purchase 11.67M shares of common stock and warrants to purchase an aggregate of 15M shares of its common stock with gross proceeds expected to be ~$45M. The shares and warrants are being sold at $3.00/share and pre-funded warrants are offered at $2.999/pre-funded warrant and accompanying warrants. Underwriters over-allotment is an additional 2.25M of shares and/or warrants to purchase up to 2.25M shares of common stock. The warrants have a seven-year term and an exercise price of $3.45/share. -Source: Seeking Alpha News April 22 The company has a long history of raising capital through messy warrants which caused the stock to tank even after the approval of Brexafemme in June 2021 (as shown below); we believe the same thing is likely to happen with any positive catalyst making the stock uninvestible. Warrants could be a catastrophe as warrant holders can start exercising their warrants and sell into the market when a stock price move above a certain level and the exercised shares were sold into the market killing the share price. SCYX data by YCharts We believe the likelihood of a potential M&A has dropped considerably at this point.
Seeking Alpha • Aug 12

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS (NASDAQ:SCYX) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.59 (-168.2% Y/Y) and the consensus Revenue Estimate is $1.64M Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Aug 01

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis (NASDAQ:SCYX) on Monday said the U.S. Food and Drug Administration (FDA) had accepted the biotech's supplemental new drug application (sNDA) to expand the label of its Brexafemme tablets to include the prevention of recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis (VVC) is a type of yeast infection caused by the fungus candida which affects the vagina and the vulva. The company said the FDA had granted the sNDA submission a priority review and was set to decide on it by Nov. 30, or the so-called Prescription Drug User Fee Act date. Brexafemme is already approved to treat VVC. Recurrent VVC would be its second indication.
Seeking Alpha • Jul 19

SCYNEXIS gains after favorable data for antifungal agent in new indication

SCYNEXIS (NASDAQ:SCYX) added ~8% in the morning hours Tuesday after the commercial-stage pharma company announced promising Phase 3 data for its oral antifungal medication ibrexafungerp in patients with recurrent vulvovaginal candidiasis (RVVC). According to the data from the 24-patient CANDLE sub-study, ibrexafungerp, an FDA-authorized therapy for vulvovaginal candidiasis, has led to clinical benefits in RVVC patients who failed to respond to another antifungal therapy called fluconazole. After one day of ibrexafungerp (300 mg BID) treatment, 71% of RVVC patients (17 of 24) were found to have a significant reduction or elimination of signs and symptoms. Additionally, these results were replicated in a subset of patients who also demonstrated positive fungal cultures post-fluconazole treatment. In this 10-patient subgroup, 80% were found to have a favorable clinical response after one-day ibrexafungerp therapy. In June, SCYNEXIS (SCYX) announced the submission of its marketing application for the label expansion of ibrexafungerp in the prevention of RVVC. The supplemental New Drug Application was backed by data from the pivotal Phase 3 CANDLE, which indicated 65% clinical success for the treatment compared to ~53% for the placebo.
Analyseartikel • Apr 07

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Today is shaping up negative for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, with the analysts delivering a...
Seeking Alpha • Mar 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

We are initiating Scynexis with a target price of USD 23 per share. SCYX offers an extremely attractive set up with 600% upside and limited downside (10-15%) considering its near cash. SCYX's Brexafemme is clinically de-risked and targets an attractive fungal infection space. Even though we expect muted uptake during 2022, we project 200M-400M peak sales within 5 years. The critical inflection point for the stock will be a business development activity from Big Pharma, not near-term earnings. The company has 100M cash, but has a high cash burn rate of around 50M/year and will likely need to raise 50-100M soon to fund its phase 3 trials. Considering close to cash value EV, we view BD activity as more likely and a public offering.
Analyseartikel • Feb 13

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Market forces rained on the parade of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders today, when the analysts downgraded...
Analyseartikel • Dec 03

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 27

Scynexis: Leading The Yeast Infection Treatment Industry

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal class in the past 20+ years. The drug has ten years of market regulatory exclusivity and patent protection until 2035. The company’s financial position is robust, with adequate cash to commercialize BREXAFEMME while continuing its current studies.

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von SCYX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von SCYX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

SCYNEXIS Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von SCYX im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (SCYX)n/a
Untere 25 % des Marktes (US)1.4%
Markt Top 25 % (US)4.3%
Branchendurchschnitt (Pharmaceuticals)2.1%
Analystenprognose (SCYX) (bis zu 3 Jahre)n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von SCYX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von SCYX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von SCYX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da SCYX keine Ausschüttungen gemeldet hat.

Entdecken Sie dividendenstarke Unternehmen

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/21 15:02
Aktienkurs zum Tagesende2026/05/21 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

SCYNEXIS, Inc. wird von 9 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Brian Kemp DolliverBrookline Capital Markets
Corey DavisCanaccord Genuity
Liisa BaykoCitizens JMP Securities, LLC